A recombinant hybrid protein as antigen for an anti-blood stage malaria vaccine.
Based on investigations on several blood stage antigens from Plasmodium falciparum we have expressed a hybrid protein in E. coli containing 262 amino acids of the serine-stretch protein SERP and 189 amino acids of the histidine alanine rich protein HRPII. Antibodies raised against the hybrid protein by immunization of rabbits and Aotus monkeys react with both corresponding schizont polypeptides. Two Aotus monkeys immunized with the SERP/HRPII hybrid protein showed only low parasitemias after challenge infection with P. falciparum, compared to the control group. The result suggests that hybrid proteins of this type may be the basis for the development of a malaria vaccine.
Knapp
B
B
Research Laboratories of Behringwerke AG, Marburg, Germany.
Hundt
E
E
Enders
B
B
Küpper
H A
HA
D000818:Animals; D000913:Antibodies, Protozoan / Q000032:analysis*; D000953:Antigens, Protozoan / Q000235:genetics / Q000276:immunology* / Q000302:isolation & purification / Q000627:therapeutic use; D001029:Aotus trivirgatus; D004247:DNA / Q000235:genetics / Q000302:isolation & purification; D004797:Enzyme-Linked Immunosorbent Assay; D008288:Malaria / Q000097:blood / Q000276:immunology* / Q000628:therapy; D010963:Plasmodium falciparum / Q000276:immunology*; D011993:Recombinant Fusion Proteins / Q000276:immunology / Q000302:isolation & purification / Q000627:therapeutic use; D015183:Restriction Mapping; D014614:Vaccines, Synthetic
D000913:Antibodies, Protozoan; D000953:Antigens, Protozoan; D011993:Recombinant Fusion Proteins; D014614:Vaccines, Synthetic; D004247:DNA